Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 169Carcinoma, Neuroendocrine 73Thyroid Neoplasms 52Pheochromocytoma 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Adrenocortical Carcinoma 40Carcinoid Tumor 39Paraganglioma 35Adenocarcinoma, Follicular 33Neoplasm Metastasis 29Neoplasms 28Somatostatinoma 26Adenoma, Islet Cell 26Insulinoma 22Carcinoma, Medullary 22Carcinoma, Islet Cell 22Pancreatic Neoplasms 21Pituitary Neoplasms 20Sarcoma 19Glucagonoma 19Gastrinoma 19Gastro-enteropancreatic neuroendocrine tumor 16Head and Neck Neoplasms 15Colorectal Neoplasms 14Multiple Endocrine Neoplasia Type 1 13Neuroblastoma 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Vipoma 11

Interventions

Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemorrhage × Endocrine × Clear all
NCT04863339 2022-04-05

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

University of North Carolina, Chapel Hill

Phase 2 Withdrawn
Endocrine

Hemorrhage, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡